SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment
3 references·6 citing·31 second hop
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment (2007)Cost-effectiveness analysis of cetuximab/…Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence? (2005)Establishing the Cost-Effecti…National Institute for Clinical Excellence and its value judgments (2004)National Institute for Clinic…Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints (1998)Extracting summary statistics…A Review and Meta-analysis of Colorectal Cancer Utilities (2014)A Review and Meta-analysis of…A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer (2013)A systematic review of cost-e…Clinical and economic challenges facing pharmacogenomics (2012)Clinical and economic challen…KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective (2011)KRAS and BRAF Mutation Analys…Cost‐effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany (2011)Cost‐effectiveness of KRAS te…Cost implications of new treatments for advanced colorectal cancer (2009)Cost implications of new trea…A systematic review of cost-effectiveness analyses of pharmacogenomic interventions (2004)Does Comparative-Effectiveness Research Threaten Personalized Medicine? (2009)Personalized medicine: Factors influencing reimbursement (2009)Financing and Reimbursement Models for Personalised Medicine: A Systematic Review to Identify Current Models and Future Options (2022)Examining the Value and Quality of Health Economic Analyses: Implications of Utilizing the QHES (2003)Criteria list for assessment of methodological quality of economic evaluations: Consensus on Health Economic Criteria (2005)Methods for the Economic Evaluation of Health Care Programmes (2005)Net Health Benefits (1998)Representing uncertainty: the role of cost‐effectiveness acceptability curves (2001)Network meta‐analysis for indirect treatment comparisons (2002)Value of Information and Value of Implementation: Application of an Analytic Framework to Inform Resource Allocation Decisions in Metastatic Hormone-Refractory Prostate Cancer (2008)The Value of Value of Information (2010)A Systematic and Critical Review of the Evolving Methods and Applications of Value of Information in Academia and Practice (2012)Systematic Overview of Cost-Utility Assessments in Oncology (2000)A Meta-Analysis of Quality-of-Life Estimates for Stroke (2003)A convenient approximation of life expectancy (the “DEALE”) (1982)A convenient approximation of life expectancy (the “DEALE”) (1982)Cost of Cancer Care: Issues and Implications (2007)Financial distress in cancer patients (2013)Cost-Effectiveness in Health and Medicine (1996)How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. (1992)EuroQol: the current state of play (1996)Decision Making in Health and Medicine: Integrating Evidence and Values (2001)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)Delivering affordable cancer care in high-income countries (2011)Probabilistic Analysis of Cost-Effectiveness Models: Choosing between Treatment Strategies for Gastroesophageal Reflux Disease (2002)The Health Utilities Index (HUI): concepts, measurement properties and applications. (2003)What Does the Value of Modern Medicine Say About the $50,000 per Quality-Adjusted Life-Year Decision Rule? (2008)Practical methods for incorporating summary time-to-event data into meta-analysis (2007)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves (2012)
this work references cited by second hop

References

  • 1998Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints4,809 cited
  • 2004National Institute for Clinical Excellence and its value judgments767 cited
  • 2005Establishing the Cost-Effectiveness of New Pharmaceuticals under Conditions of Uncertainty—When Is There Sufficient Evidence?121 cited

Cited by

  • 2012Clinical and economic challenges facing pharmacogenomics70 cited
  • 2011KRAS and BRAF Mutation Analysis in Metastatic Colorectal Cancer: A Cost-effectiveness Analysis from a Swiss Perspective66 cited
  • 2011Cost‐effectiveness of KRAS testing in metastatic colorectal cancer patients in the United States and Germany65 cited
  • 2009Cost implications of new treatments for advanced colorectal cancer61 cited
  • 2013A systematic review of cost-effectiveness of monoclonal antibodies for metastatic colorectal cancer59 cited
  • 2014A Review and Meta-analysis of Colorectal Cancer Utilities57 cited

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work